All In Biotech

Drug Trial Radar · NCT07488897

RIG 101 Trial in Healthy Adults and Adults With Asthma

A Two-part Randomized, Double-blind Placebo Controlled Trial to Assess the Safety and Tolerability of Single and Repeat Ascending Intranasal Doses of RIG-101 in Healthy Participants Followed by Repeat Daily Administration in Adult Participants With Asthma [Part A] Followed by a Randomized Double-blind Placebo Controlled Part to Assess the Efficacy and Safety of RIG-101 in Adult Participants With Asthma Before and After Viral Challenge With Human Rhinovirus RV-A16 [Part B].

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Feb 9, 2026

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
RIGImmune Inc.Industry
Sponsor type
Industry
Collaborators
Virtus Respiratory Research; Medicines Evaluation Unit Ltd
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy

Conditions

  • Healthy Adult Participants
  • Asthma Exacerbation
  • Safety and Efficacy

Interventions

  • RIG-101Drug

    Single, and repeat escalating intranasal administrations of RIG-101

  • PlaceboOther

    Single and repeat Intranasal administrations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1-35
  2. Systolic/Diastolic blood pressureTime frame: Day 0 - 35
  3. Physical examinationsTime frame: Day 0 -35
  4. Nasal examinationsTime frame: Day 0 - 35
  5. Spirometry (FEV₁ and FVC)Time frame: Day 0-35
  6. Triplicate 12-lead ECGs and single 12-lead ECGsTime frame: Day 0 - 35
  7. Safety laboratory testing-haematologyTime frame: Day 0 - 35
  8. Safety laboratory testing-Serum ChemistryTime frame: Day 0- 35
  9. Safety laboratory testing-CoagulationTime frame: Day 0 -35
  10. Lower respiratory tract symptom score assessmentsTime frame: Day -7 to 35
  11. AUC of Lower respiratory tract symptom scoreTime frame: Day -7 to 35
  12. Vital Signs - heart rateTime frame: Day 0 - 35

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Virtus Respiratory Research Ltd

    London, United Kingdom · Recruiting

  • Medicines Evaluation Unit

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.